FDA Grants Fast Track Status to Stem Cell-Viral Therapy for Advanced Cancers
Calidi’s CLD-201, a novel stem cell-based oncolytic virus therapy, moves forward.
Calidi Biotherapeutics has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy CLD-201 (SuperNova), an allogeneic adipose stem cell-loaded oncolytic virus, for the treatment of soft tissue sarcoma.
Fast Track designation is intended to facilitate the development and review of therapies targeting serious or life-threatening conditions with unmet medical needs. This status provides Calidi with increased interactions with the FDA and the potential for priority review and accelerated approval pathways.
Calidi plans to initiate a Phase 1 first-in-human, open-label, multicenter trial to evaluate the safety, tolerability, and efficacy of CLD-201 in patients with soft tissue sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma.
Guy Travis Clifton, M.D., Chief Medical Officer of Calidi, commented, “FDA IND clearance and Fast Track designation represents an important milestone in the development of CLD-201. This designation underscores the unmet medical need in sarcoma and provides scientific and regulatory validation of CLD-201. We believe CLD-201 has the potential to provide durable and transformational treatment to patients with sarcoma as well as patients with other advanced tumor types. We want to thank the FDA for its support and partnership and look forward to continued collaboration with the agency.”
CLD-201 is comprised of adipose-derived mesenchymal stem cells (AD-MSCs) that are loaded with an oncolytic vaccinia virus. This approach is designed to protect the virus from immune clearance and allow it to amplify within the stem cells, potentially increasing potency and immune activation. The therapy is being developed for use in advanced solid tumors, including sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma.
While CLD-201 remains in early development and clinical data are not yet available, the Fast Track status is a regulatory milestone that could shorten the timeline to potential approval for this therapy. Calidi is also pursuing the development of additional virotherapies targeting other tumor types with significant unmet needs.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
